CIK 0000882796
- Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 621413174
- Phone
- +1 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-19 | Doyle Anthony Chief Financial Officer | Grant or award | +120,700 | 380,328 | ||
| 2024-12-19 | Doyle Anthony Chief Financial Officer | Shares withheld for taxes | −2,461 | $7.39 | $18K | 377,867 |
| 2024-12-19 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +250,100 | 250,100 | ||
| 2024-12-14 | Doyle Anthony Chief Financial Officer | Shares withheld for taxes | −7,890 | $7.53 | $59K | 259,628 |
| 2024-05-14 | Doyle Anthony Chief Financial Officer | Purchase | +36,300 | $5.57 | $202K | 266,744 |
| 2023-12-19 | Doyle Anthony Chief Financial Officer | Shares withheld for taxes | −2,482 | $6.05 | $15K | 227,444 |
| 2023-12-14 | Doyle Anthony Chief Financial Officer | Grant or award | +34,000 | 235,401 | ||
| 2023-12-14 | Doyle Anthony Chief Financial Officer | Shares withheld for taxes | −5,475 | $6.43 | $35K | 229,926 |
| 2023-12-14 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2022-12-19 | Doyle Anthony Chief Financial Officer | Grant or award | +34,000 | 197,966 | ||
| 2022-12-19 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +158,500 | 158,500 | ||
| 2022-12-15 | Doyle Anthony Chief Financial Officer | Sale | −5,700 | $10.90 | $62K | 163,966 |
| 2021-12-14 | Doyle Anthony Chief Financial Officer | Grant or award | +75,000 | 168,719 | ||
| 2021-12-14 | Doyle Anthony Chief Financial Officer | Grant or award | +115,000 | 208,719 | ||
| 2021-12-14 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +164,000 | 164,000 | ||
| 2021-11-23 | Doyle Anthony Chief Financial Officer | Purchase | +35,258 | $12.48 | $440K | 93,719 |
| 2020-12-15 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +332,500 | 332,500 | ||
| 2020-08-11 | Doyle Anthony Chief Financial Officer | Purchase | +54,000 | $4.08 | $220K | 54,000 |
| 2020-04-30 | Doyle Anthony Chief Financial Officer | Grant or award · Emp. Stock Option (Right to Buy) | +600,000 | 600,000 |
Page 1 of 1 · 19 trades